Search jobs Immunodiagnostics and Vaccine Development at Viravaxx AG Gain Momentum Vienna (Austria), Jan 11, 2021. Fast-track development of vaccines against COVID-19 and other infectious diseases are facilitated by microarray-based assays for whole-proteome analysis and vaccine design platforms. Both have been developed by Viravaxx AG, and the company’s recent progress with its SARS-CoV-2 Interaction Assay offered a turning point.
Concomitantly, as of Jan 1, 2021, Viravaxx has recruited Dr. Helmut Brunar as its new CEO. Dr. Brunar brings vast expertise in vaccines, cell-therapies and diagnostic products to the company. Before joining Viravaxx, he managed supply chain activities at Johnson & Johnson’s COVID-19 vaccine program. Prior to this, he was CEO & Chairman with Axentis Pharma AG where he built a team to develop respiratory drug candidate AX-TOBRA. Dr. Brunar will take over from Dr. Rainer Henning, who has made invaluable contributions for establishing the company at the forefront of innovative immunodiagnostics and vaccine development.